TARGETING RECEPTOR KINASES BY A NOVEL INDOLINONE DERIVATIVE
IN MULTIPLE MYELOMA:
ABROGATION OF STROMA-DERIVED INTERLEUKIN-6 SECRETION AND
INDUCTION OF APOPTOSIS IN CYTOGENETICALLY DEFINED SUBGROUPS

Guido Bisping1*, Martin Kropff1*, Doris Wenning1, Britta Dreyer1, Sergey Bessonov1, Frank Hilberg2, Gerald J. Roth3, Gerd Munzert3, Martin Stefanic3, Matthias Stelljes1, Christian Scheffold1, Carsten Müller-Tidow1, Peter Liebisch4, Nicola Lang5, Jöelle Tchinda6, Hubert L. Serve1, Rolf M. Mesters1, Wolfgang E. Berdel1 and Joachim Kienast1

From the Department of Medicine / Hematology and Oncology, University of Muenster, Muenster, Germany1, Boehringer Ingelheim Austria GmbH, Vienna, Austria2 and Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany3  
4Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany,  
5University Hospital Großhadern, Department of Medicine III, Ludwig-Maximilians-University, Munich, Germany,  
Institute of Human Genetics, University of Muenster, Muenster, Germany 6

Short title: BIBF 1000 in multiple myeloma
Scientific section heading: Neoplasia
Key words: myeloma, VEGF, bFGF, IL-6, receptor tyrosine kinases
* G.B. and M.K. contributed equally to this work

Address correspondence to:
J. Kienast, MD
Department of Medicine / Hematology and Oncology
University of Muenster, Albert-Schweitzer-Str. 33, D- 48129 Muenster, Germany
Phone + 49 - 251 - 83 - 5 28 01
Fax + 49 - 251 - 83 - 5 28 04
Email: kienast@uni-muenster.de

*Several of the authors (F.H. (Frank Hilberg); G.M. (Gerd Munzert); G.J.R. (Gerald J. Roth), M.S. (Martin Stefanic)) are employed by Boehringer Ingelheim Austria GmbH
and/or Boehringer Ingelheim Pharma GmbH & Co. KG whose product was studied in the present work.

Abstract

In multiple myeloma (MM), both vascular endothelial (VEGF) and basic fibroblast growth factor (bFGF) promote tumor growth and survival. We have used the novel indolinone BIBF 1000 to study effects of simultaneous inhibition of VEGF, FGF and transforming growth factor-β on MM cells and their interactions with bone marrow stroma cells (BMSCs). Both, in the absence and presence of myeloma-stroma cell contacts, BIBF 1000 abrogated BMSC-derived secretion of interleukin-6 (IL-6). In addition, BIBF 1000 directly induced apoptosis in t(4;14) positive cell lines as well as in CD138+ marrow cells from patients with t(4;14) myeloma. To a similar extent, BIBF 1000 induced apoptosis in MM.1S and MM.1R cells carrying the translocation t(14;16). In case of MM.1S and other dexamethasone-sensitive t(14;16) cell lines, BIBF 1000 and dexamethasone had additive proapoptotic effects. Induction of apoptosis by BIBF 1000 was associated with inhibition of the mitogen-activated protein kinases (MAPK) pathway in t(4;14) and inhibition of the phosphatidyl-inositol-3 kinase/AKT pathway in t(14;16) cells. Apoptotic effects did not occur in t(4;14) or t(14;16) positive MM cells carrying n- or k-Ras mutations. The data provide the rationale for clinical evaluation of this class of targeted kinase inhibitors in MM with focus on defined cytogenetic subgroups.
Introduction

A new generation of targeted antineoplastic agents has opened perspectives to more selective treatment of hematological malignancies and solid cancers. These agents interfere with oncogenic signaling events intrinsic to the tumor cell or with survival, expansion and spreading signals arising from the tumor environment. Along the lines of such biologically based therapies, considerable progress has been made in the treatment of multiple myeloma (MM), a malignant plasma cell disorder still considered incurable despite recent treatment advances. Novel agents in MM therapy include thalidomide, its immunomodulatory derivative CC-5013 (lenalidomide, Revlimid®), the proteasome inhibitor bortezomib (Velcade®, formerly PS-341), and arsenic trioxide. These drugs not only have marked antimyeloma activity, but also appear suited to overcome classical drug resistance.

Small molecule tyrosine kinase inhibitors represent a separate class of targeted drugs. As an outstanding example of their therapeutic potential, imatinib (Gleevec®, formerly STI571) has proven remarkably effective in the treatment of chronic myeloid leukemia by inhibition of the Abl kinase that is deregulated as a consequence of the oncogenic Bcr/Abl gene fusion. Related compounds, designated receptor tyrosine kinase inhibitors (RTKIs), hold promise as antineoplastic agents by interference with receptor-mediated extrinsic tumor growth and survival signals. RTKIs with different receptor specificities are currently under investigation in various malignancies.

In MM, evidence accumulated over the past years has provided a solid rationale for the evaluation of RTKIs targeting receptors of vascular endothelial growth factor (VEGF) and of basic fibroblast growth factor (bFGF). Both angiogenic cytokines are expressed and secreted by myeloma cells and contribute to myeloma-associated bone marrow neovascularization. They both have been
shown to stimulate bone marrow stroma cells (BMSCs) to produce interleukin-6 (IL-6), an important growth and survival factor for human MM. In turn, IL-6 enhances the production and secretion of VEGF and bFGF by myeloma cells. 

Besides these paracrine loops optimizing the micromilieu for MM tumors, VEGF stimulates myeloma cell proliferation and migration in an autocrine manner.

Circumstantial evidence also suggests an autocrine circuit for bFGF. In addition, constitutively activated mutant FGF receptor 3 (FGFR3) in MM cells carrying the translocation t(4;14) functions as an oncogene that contributes to tumor progression in experimental models. Finally and most recently, it has been demonstrated that frequent overexpression of the c-maf oncogene in MM enhances VEGF secretion in cocultures of myeloma cells and BMSC. Taken together, these data suggest a pivotal role for VEGF and bFGF as survival and expansion factors in human MM.

We have used a novel RTKI, the indolinone derivative BIBF 1000 that competitively binds to the ATP binding sites within the kinase domains of VEGFR1 through VEGFR3, FGFR1, FGFR3, and PDGFRα in order to study in vitro effects of the inhibition of VEGF and bFGF signaling on MM cells and their stromal microenvironment. The study was also aimed at assessing the antmyeloma activity of BIBF 1000 in MM cell lines with translocations of the immunoglobulin heavy-chain (IgH) locus leading to dysregulation of the oncogenic partner regions FGFR3/MMSET at 4p16.3 and c-maf at 16q23, respectively.
Materials and methods

Patients

Bone marrow samples from patients with active MM and peripheral blood samples from healthy volunteers were studied. Patients and volunteers gave written informed consent prior to the sampling procedure. This study was supported by research funding from Boehringer Ingelheim Pharma GmbH & Co. KG to G.B. and J.K.

Reagents

A 0.2 M stock solution of the investigational small molecule inhibitor BIBF 1000 synthesized in a medicinal chemistry program was prepared in DMSO. To obtain adequate working concentrations, the stock solution was diluted with ddH₂O containing at least 0.005 % DMSO. Dexamethasone (Dex) was purchased from Sigma-Aldrich (Munich, Germany). The phosphatidylinositol-3 kinase (PI-3K) inhibitor Ly292004 and the mitogen-activated-protein kinases (MAPK) inhibitor PD98059 were obtained from Calbiochem (San Diego, CA, USA). The pan-caspase inhibitor z-VAD-FMK was delivered by Enzyme Systems (Livermore, CA, USA). Recombinant human VEGF₁₆₅, VEGF₁₂₁, transforming growth factor-β (TGF-β), tumor necrosis facor-α (TNF-α), interleukin-1β (IL-1β), IL-6 and neutralizing anti-bFGF and anti-VEGF antibodies were purchased from R&D Systems (Wiesbaden, Germany). Basic FGF was supplied from Roche Diagnostics (Mannheim, Germany). The carboxy-fluorescin diacetate succimidyl ester (CFSE), a fluorescent impermanent membrane dye, was obtained from Renovar (Madison, WI, USA). Annexin-V-FITC, Apo2.7, and propidium iodide (PI) were purchased from BD Sciences/Clontech (San Jose, CA, USA), anti-CD38-phycoerythrin/cyanin5 from Coulter-Immunotech
(Hamburg, Germany), and anti-CD138-fluorescein isothiocyanate from Serotec (Oxford, UK). Murine monoclonal antibodies against human CD54, CD68, CD31, and thrombomodulin came from DAKO (Glostrup, Denmark) and were used for phenotypic characterization of BMSCs. Rabbit polyclonal antibodies raised against KDR, phospho-MAPK (p44/42), phospho-STAT3 (Tyr705), and phospho-AKT (Ser473) as well as anti-phospho-tyrosine antibodies (mouse monoclonal anti-p-Tyr-100 and rabbit anti-p85 PI3-K binding motif, respectively) and the corresponding goat anti-rabbit- or goat anti-mouse-horseradish peroxidase conjugated secondary antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA). Rabbit polyclonal FGFR3 raised against a recombinant protein corresponding to amino acids 25-124 of the extracellular receptor domain was supplied from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). Monoclonal anti-β actin (clone AC-15) came from Sigma (Saint Louis, MI, USA) and ³H-thymidine (5.0 Ci/mmol, 1.0 mCi/mL) from Amersham (Buckinghamshire, UK).

Tyrosine kinase assays

The inhibitory activity and specificity of BIBF 1000 was determined in biochemical assays measuring autophosphorylation of receptor tyrosine kinases of VEGF receptors (VEGFRs), FGFRs, platelet derived growth factor receptor α (PDGFRα), epidermal growth factor rector (EGFR), human epidermal growth factor receptor-2 (HER-2), insulin receptor (InsR), insulin growth factor receptor (IGFR), and hepatocyte growth factor receptor (HGFR). In addition, inhibition of autophosphorylation of the cyclin dependent kinases CDK1, CDK2 and CDK4 by BIBF 1000 was determined. The assays were performed using recombinant clones of baculovirus constructs containing GST fusion proteins of the cytoplasmatic kinase domains of these receptors. ²⁰, ²¹
**Immunofluorescent labeling and cell sorting**

Bone marrow mononuclear cells (MNCs) from patients with active MM were separated by density gradient centrifugation using Ficoll-Paque at 1172 x g for 20 minutes (Pharmacia, Upsala, Sweden). CD38\textsuperscript{high}/CD138\textsuperscript{+} plasma cells were isolated from the marrow MNC fraction by fluorescence-activated cell sorting using a FacsVantage (Becton Dickinson). On reanalysis, sorted myeloma cell populations had a purity of at least 95% for the CD38\textsuperscript{high}/CD138\textsuperscript{+} phenotype. CD19\textsuperscript{-}/CD14\textsuperscript{-} B lymphocytes (PBBLs) for control experiments were sorted from peripheral blood MNCs of healthy volunteers. CellQuest pro software (BD Sciences) was used for flow cytometric analyses.

**Cell cultures**

The human myeloma-derived cell lines RPMI-8226, U-266, OPM-2, NCI-H929, L363, and JJN-3 were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). KMS-11 and KMS-18 were kindly provided by T. Otsuki, Kawasaki Medical School, Okayama, Japan, the cell lines MM.1S and MM.1R by Nancy L. Krett, Robert H. Lurie Comprehensive Cancer Center, Chigago, Illinois, USA, the cell lines OCI-My5 and UTMC-2 by Leif Bergsagel, Mayo Clinic, Scottsdale, Arizona, USA, and ANBL-6 by M. Chatterjee, Max-Delbrueck Zentrum, Berlin-Buch, Berlin, Germany. Cell lines and CD38\textsuperscript{high}/CD138\textsuperscript{+}-sorted marrow myeloma cells from patients were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium with 10% fetal calf serum (FCS; Gibco-BRL, Eggenstein, Germany). Cultures of BMSCs from MM patients (MM-BMSCs) were established from the MNC fraction of marrow aspirates according to the method of Lagneaux et al \textsuperscript{22} with minor modifications as described \textsuperscript{6, 7} and
maintained in MEM-alpha medium (Gibco-BRL). All culture media were supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin (Biochrom, Berlin, Germany), and 2 mmol/L L-glutamine (GIBCO-BRL). Cultures were maintained at 37°C and 5% CO2.

For cytokine secretion experiments, BMSCs in passages 2 to 4 were grown in 24-well plates. Prior to stimulation with exogenous cytokines or exposure to BIBF 1000, confluent layers were starved for 12 hours (1% FCS). During the stimulation period, BMSCs were kept in serum-free conditions.

Co-cultures were established using a transwell system (pore size 0.4 µm, Nunc, Wiesbaden, Germany) precluding direct cell-cell contacts, with myeloma cells seeded in the inserts at a density of $2 \times 10^5$/mL and confluent BMSCs growing on the bottom of the plates. Contact co-cultures were established by directly seeding myeloma cells ($2 \times 10^5$/mL) onto confluent BMSCs.

**Cytokine stimulation of cell cultures and exposure to BIBF 1000**

BMSC monocultures were stimulated with recombinant human VEGF$_{165}$ (50 ng/mL), VEGF$_{121}$ (50 ng/mL), bFGF (10 ng/mL), TGF-β (10 ng/mL), TNF-α (10 ng/mL), or IL-1-β (10 ng/mL) for 72 hours in serum-free conditions ± BIBF 1000 (0.5 µM). Transwell and contact co-cultures of BMSCs and myeloma cells were run in the absence or presence of BIBF 1000 (0.125 – 1.0 µM, 72 hours) under serum-free conditions.

**IL-6 assay**

Cell culture supernatants were analyzed for IL-6 using a commercial enzyme-linked immunosorbent assay (ELISA; Quantikine®, R&D Systems) with a lower detection limit of 0.7 pg/mL. Calibration curves were prepared by dilution of the IL-6
standard provided by the manufacturer. Concentrations of IL-6 are presented as pg/mL corrected for $10^6$ cells.

**RNA preparation and cDNA synthesis**

Total RNA was prepared using the guanidine isothiocyanate/phenol method\(^{19}\) (Trizol® Reagent, Invitrogen, Life Technologies, Karlsruhe, Germany). Complementary DNA (cDNA) was synthesized for 1 hour at 37°C, using 1 µg total RNA, 40 U/µl RNA guard (Amersham, Pharmacia, Piscataway, NJ), 100 pmol/µL random hexamers (Amersham, NJ), 200 U M-MLV reverse transcriptase (Gibco BRL, Life Technologies, Karlsruhe, Germany), 5 x first strand buffer (250 mM Tris-HCl, 375 mM KCl, 15 mM MgCl₂, and 0.1 M DTT), 80 mM dNTPs (Amersham, NJ), and 1 µg/mL bovine serum albumine (BSA, Serva, Heidelberg, Germany).

**Analysis of N-Ras and K-RAS mutations**

The cDNA from myeloma cells enriched by fluorescent cell sorting was amplified by polymerase chain reaction with primers spanning the mutation hotspots codons 12, 13, and 61. The following primers were used: N-RAS forward TTT CCC GGT CTG TGG TCC TAA AT, N-RAS reverse CTT CGC CTG TCC TCA TGT ATT GG, K-RAS forward CGG CTC GGC CAG TAC TCC, and K-RAS reverse TCT TGC TAA GTC CTG AGC CTG TTT. PCR products were verified by agarose gel electrophoresis and purified. Direct cycle sequencing was performed for both strands using the same primers as for PCR reaction.

**Fluorescence in situ hybridization (FISH) analysis**

Fluorescence in situ hybridization (FISH) was used to examine the samples for deletions of the chromosome region 13q14.3 or monosomy 13 as well as for
rearrangements of the IgH gene locus. FISH was performed according to the manufacturer’s instructions using commercially available probes. All probes were purchased from Abbott (Wiesbaden, Germany). The following probes have been used: LSI ® D13S319 (13q14.3) SpectrumOrange TM Probe, LSI ® 13q34 Spectrum GreenTM Probe, LSI ® IGH Dual Color Break Apart Rearrangement Probe, and LSI ® IGH/FGFR3 Dual Color Dual Fusion Translocation Probe.

**Immunoblotting of receptors and signaling molecules**

BMSCs were starved for 4 hours and subsequently exposed to VEGF$_{165}$ (50 ng/mL), bFGF (10 ng/mL), TGF-β (10 ng/mL), TNF-α (10 ng/mL), or IL-1-β (10 ng/mL) for 2 hours in the absence or presence of BIBF 1000 (39 nM to 20 µM) or the MAPK inhibitor PD98059 (20 µM). Cultured myeloma cells were starved for 4 hours prior to stimulation with IL-6 (10 ng/mL) in the absence or presence of BIBF 1000 (39 nM to 20 µM) for 5 minutes.

Thereafter, cells were harvested, washed 3 times in PBS, and lysed by RIPA-buffer (150 mM NaCl, 1% Nonidet P-40, 0.5 % deoxycholate, 0.1 % SDS, 50 mM Tris base, pH 8.0) supplemented with a protease inhibitor mix (phenyl-methyl-sulfonyl fluoride, leupeptin, aprotinin, β-mercaptoethanol, Boehringer Mannheim) and the phosphatase inhibitors NaF (25 nM, Sigma) and NaVO$_4$ (2,5 nM, Sigma). Protein content in lysates was measured by a modified Bradford assay.$^{23, 24}$ Prior to electrophoresis, proteins were denaturated and boiled in Laemmli buffer.$^{25}$ Protein samples were electrophoretically separated on 8% SDS-polyacrylamide gels. Prestained molecular weight markers (Bio-Rad, Munich, Germany) served for protein size control. Separated proteins were transferred from the gels onto PVDF-membranes (Millipore, Billerica, MA, USA) by a semidy blotting procedure with 0.8 mA/cm$^2$ current for two hours. Subsequently, membranes were blocked with 2% milk
powder (Roth, Karlsruhe, Germany) followed by hybridization at 4°C over night using
the following primary antibodies: anti-KDR, anti-phospho-tyrosine, anti-phospho-
MAPK (p44/p42), anti-phospho-STAT3 (Tyr705), anti-phospho-AKT (Ser473), and
anti-FGFR3, respectively. Anti-β actin served as control for equal protein loading.
Membranes were then incubated with the corresponding species specific
horseradish-peroxidase(HRP)-linked secondary antibodies. Finally, blots were
soaked in Luminol reagent (Santa Cruz) and exposed to autoradiography films
(BML-1, Kodak, Stuttgart, Germany).

For immunoprecipitation of VEGFR2 (KDR), 200µL of cell lysates were incubated
with anti-KDR overnight at 4°C followed by addition of protein G agarose beads for
12 hours. Samples were centrifuged, washed in lysis buffer, resuspended in sample
buffer and subsequently separated by electrophoresis. Immunoprecipitates were
blotted onto PVDF-membranes and hybridized with the corresponding anti-phospho-
tyrosine antibody. Blot signals were quantified densitometrically using BioRad
Quantity One Software (Version 4.5.1).

Quantification of apoptotic cells

Myeloma cell lines were collected after 24 hours of exposure to BIBF 1000
(0.125 – 0.5 µM), dexamethasone (10⁻⁵ M), IL-6 (10 ng/mL), and z-VAD-FMK (100
µM), respectively, either alone or in combinations. Cells were washed in PBS,
resuspended in binding buffer containing 10 mM HEPES/NaOH, 140 mM NaCl, 2.5
mM CaCl₂, pH 7.4, and stained with fluoroisothiocyanate (FITC)-coupled Annexin V
and PI.²⁶ Due to the limited amount of CD 138⁺ patient myeloma cells collected, in
vitro short term exposure (up to 24 hrs) was performed only with BIBF 1000 (0.5 µM)
and, if possible, with dexamethasone (10⁻⁵ M), IL-6 (10 ng/mL) or their combinations.
Flow cytometric analysis for quantification of apoptotic cells was performed using a Becton Dickinson FACSCalibur (BD Sciences). CellQuest pro software (BD Sciences) was applied for flow cytometric analyses. Data are presented as dot plots or histograms of at least 10,000 counted events per sample.

In cultured BMSCs, apoptosis was quantified by an Apo2.7 assay. Cells were detached from the bottom of the culture plates by short term incubation in Versen’s solution (10 mM EDTA, 137 mM NaCl, 2.6 mM KCl, 8.1 mM NaH$_2$PO$_4$, 1.4 mM KH$_2$PO$_4$, 1.1 mM Glucose), subsequently fixed in 1 % paraformaldehyde, permeabilized and stained with phycoerythrin (PE)-conjugated Apo2.7 antibody and co-stained with CD56-FITC.

**Proliferation assay**

5 x 10$^4$ myeloma cells per well were seeded onto 96 well plates, pulsed with 0.625 µCi $^3$H-thymidine per well and cultured in RPMI-1640 in the absence or presence of BIBF 1000 for 72 hours. Thereafter, cells were harvested and $^3$H-thymidine incorporation was measured in a Microbeta 1450 counter (Wallac, Turku, Finland). All samples were assayed in triplicates. $^3$H-thymidine uptake was normalized to controls for each cell line.

**Myeloma cell adhesion assay**

Myeloma cells were labeled with CFSE (5 µM) in serum-free PBS for 5 minutes. Intracellular esterases are known to convert diffusible CFSE to an impermanent membrane-bound fluorescent dye by cleavage of acetate groups. CFSE is not transferred to adjacent cells. After intensive washing in RPMI 1640 with 10 % FCS, CFSE-labeled myeloma cells (2 x 10$^6$ cells per well) were added to confluent monolayers of 10$^5$ unstained BMSCs. Adhesion co-cultures were incubated in the
absence or in the presence of increasing concentrations of BIBF 1000 for 24 hours. Subsequently, non-adherent cells were washed off three times and the remaining adherent myeloma and stroma cells were trypsinized. Ratios of the adherent CFSE-stained myeloma cells and unstained BMSCs were quantified by flow cytometry.

**Statistics**

Data other than immunoblotting results are presented as individual data plots or as means ± SE. Statistical analyses were done with SPSS package, Version 12.0. Statistical significance of overall differences between multiple groups was analyzed by the Kruskal-Wallis one-way analysis of variance. If the test was significant, pairwise comparisons were done by the multiple-comparisons' criterion. Differences between two independent groups were analyzed by the Mann-Whitney rank sum test. The Wilcoxon matched-pair signed rank test was used for comparison of differences within pairs. A $P$ value of .05 or less was considered significant.
Results

Kinase inhibition by BIBF 1000

As determined in biochemical kinase assays and described in detail elsewhere,20, 21 BIBF 1000, a novel small molecule RTKI, effectively targets VEGFRs 1 through 3, FGFRs 1 and 3 as well as PDGFR α. If at all, the receptor tyrosine kinase activities of EFGR, HER-2, IGFR-1, Ins-R, HGFR, as well as CDK1, CDK2, and CDK4 are not substantially inhibited by BIBF 1000. The inhibitory concentration of 50 % (IC₅₀) values for the respective receptor tyrosine kinases are listed in Table 1.

Inhibition of VEGFR2 and FGFR3 phosphorylation in cell cultures

We have previously shown that BMSCs express the angiogenic growth factor receptor VEGFR2 (KDR/Flk-1) and that receptor binding of VEGF₁₂₁ and VEGF₁₆₅ stimulates IL-6 release from marrow stroma cells.⁶ Therefore, we first tested inhibition of VEGF-dependent VEGFR2 phosphorylation by BIBF 1000 in cultures of BMSCs. Ligand-induced phosphorylation of the receptor was abrogated by BIBF 1000 at micromolar concentrations and substantially inhibited in the nanomolar concentration range (Figure 1A).

In order to further confirm the receptor specificity of BIBF 1000, we also studied its effects on FGFR3 tyrosine kinase phosphorylation. For these experiments, we chose the myeloma cell line OPM-2 known to overexpress the constitutively active K650E mutation of FGFR3.¹⁶ As illustrated in Figure 1B, autophosphorylation of the tyrosine kinase domain was inhibited by BIBF 1000 in a dose-dependent manner and at concentrations comparable to those inhibiting VEGFR2 phosphorylation.
Effects of BIBF 1000 on BMSC-derived IL-6 release and related inhibition of MAPK phosphorylation

Besides VEGF and bFGF, other cytokines secreted by myeloma cells including TGF-β, TNF-α, and IL-1β are known to induce IL-6 release from BMSCs. This paracrine IL-6 release protects myeloma cells from apoptosis, promotes myeloma cell proliferation and survival, and confers drug resistance. In the presence of BIBF 1000 (0.5 µM), IL-6 secretion from cultured BMSCs under basal conditions and, as expected, upon exposure to either VEGF121,VEGF165 or bFGF was significantly inhibited (p<.001, Figure 2 A). In addition, we found that the 4fold increased stromal IL-6 release induced by TGF-β was also strongly antagonized by BIBF 1000 (n=4, p<.001, Figure 2 B). In contrast, IL-6 release induced by TNF-α or IL-1-β was not significantly reduced by BIBF 1000 (Figure 2 B). The data suggest that, in addition to the targeted receptor tyrosine kinases, BIBF 1000 also interferes with paracrine TGF-β-mediated effects in the myeloma microenvironment. The viability of BMSC was not affected by BIBF 1000 in the nanomolar concentration range (data not shown).

Since MAP kinases are final effectors of VEGF and bFGF signaling to the nucleus, secondary effects of BIBF 1000 on MAPK (p44/42) phosphorylation in BMSCs were evaluated next. Inhibition of MAPK phosphorylation by the study drug was detectable in unstimulated cultures (not shown) and was most marked in BMSCs stimulated with either VEGF or bFGF. A similar effect was observed in control experiments with the MAPK inhibitor PD98059 (Figures 2 C a, b and f). In BMSCs exposed to TGF-β, BIBF 1000 turned out to be almost equally potent inhibiting MAPK phosphorylation; Figure 2 C c). Although Sma and Mad related proteins (SMADs) are the preferred substrates and signal transducers of TGF-β receptors, there is ample
evidence indicating that, in line with our observation, TGF-β may also signal through MAPK pathways. Consistent with the above results on stimulation of IL-6 release, MAPK phosphorylation in BMSCs exposed to TNF-α or IL-1β was distinctly less sensitive to equimolar concentrations of BIBF 1000 (Figures 2 C d and e). Taken together, these observations suggest that the MAPK pathway is involved in IL-6 production of marrow stroma cells induced by VEGF, bFGF and TGF-β and that in addition to VEGF- and bFGF-, also TGF-β-induced MAPK phosphorylation can be inhibited by BIBF 1000.

**Abrogation of IL-6 secretion by BIBF 1000 in co-cultures of myeloma and marrow stroma cells**

In the bone marrow microenvironment, myeloma cells induce IL-6 secretion from stroma cells through both cytokine-mediated paracrine mechanisms and cellular adhesion. Effects of BIBF 1000 on myeloma cell-induced IL-6 release from BMSCs were therefore studied in both transwell and contact co-cultures. In both types of co-cultures, IL-6 secretion was significantly higher than in monocultures of BMSCs and myeloma cells, respectively. BIBF 1000 (0.125 – 1.0 µM) inhibited IL-6 secretion in a dose-dependent manner in both transwell and contact co-cultures of BMSCs and myeloma cell lines or myeloma cells purified from bone marrow of MM patients. (Figure 3).

**Effects of BIBF 1000 on myeloma cell adhesion**

It has been demonstrated that adhesion of myeloma cells to BMSCs through surface molecule interactions mediates homing, drug resistance and protection of the malignant cells from apoptosis. Furthermore, myeloma cell adhesion induces
transcription and secretion of anti-apoptotic growth and survival factors such as insulin growth factor (IGF), VEGF, or IL-6.\textsuperscript{41, 42, 47} We therefore examined the influence of BIBF 1000 on adhesion of myeloma cell lines to cultured BMSCs. We found very significant and sensitive inhibition of stromal adherence for several myeloma cell lines including U-266 and t(4;14) positive OPM-2 and KMS-11. In contrast, adhesion of k-Ras-mutated RPMI-8226 cells to BMSCs was resistant to BIBF 1000 (Figure 4). The results suggest that decreased myeloma cell adhesion may contribute to the observed inhibition of IL-6 secretion by BIBF 1000 in contact co-cultures with BMSCs. However, the data obtained with RPMI-8226 demonstrate that targeting paracrine signaling through VEGF, bFGF and TGF-β even in the presence of maintained myeloma-stroma cell adherence is sufficient for relevant inhibition of IL-6 release in the myeloma microenvironment (compare Figure 3 G).

**Inhibition of myeloma cell proliferation**

In order to further characterize in vitro activities of BIBF 1000, we also studied its effects on myeloma cell proliferation using a \(^3\)H-thymidine uptake assay. As illustrated in Figure 5, there was a dose-dependent inhibition of proliferation over the nanomolar concentration range of BIBF 1000. However, it was again evident that the sensitivity of myeloma cell lines varied. While RPMI-8226, JJN-3 and ANBL-6 cells were relatively resistant (Fig. 5 B; white circle, grey-filled circle, and grey-filled square), U-266 and L-363 showed intermediate sensitivity with 30 to 50 % inhibition of proliferation in the presence of 0.5 to 1.0 µM BIBF 1000 (Fig. 5 C; black-filled circle, and black-filled square). Notably, most marked effects on proliferation were observed in the t(4;14) positive, FGFR3 overexpressing KMS-11, OPM-2 and NCI-H929 cells\textsuperscript{15, 16, 48} (Fig. 5 A) and in the t(14;16) positive, VEGFR1 expressing MM.1S and MM.1R cells (Fig. 5 B; black-filled circle, and black-filled square).\textsuperscript{13} In these cell
lines, proliferation was inhibited by ≥ 70% at 1.0 μM BIBF 1000 (P<.001 for each cell line versus control without BIBF 1000, Kruskal-Wallis-Test).

**Induction of apoptosis in t(4;14) myeloma cells and related inhibition of the MAPK pathway**

In line with the subgroup-selective effects on proliferation, we also observed significant induction of apoptosis by BIBF 1000 (0.5 μM) in the t(4;14) FGFR3 mutated cell lines KMS-11, KMS-18, OPM-2 and UTMC-2 (p < .05, Table 2). Additive effects on induction of apoptosis were shown when coincubating KMS-11 and OPM-2 with BIBF 1000 and dexamethasone (p ≤ .05, Table 2). As detailed below, a series of t(4;14) positive myeloma patients was also found to be sensitive to induction of apoptosis by BIBF 1000 (Table 2 and Fig. 8). BIBF 1000-induced apoptosis in t(4;14) myeloma cells was dose-dependent, completely inhibited by the pan-caspase inhibitor z-VAD (Figure 6A) and tended to be partially antagonized by IL-6 (Table 2). Proapoptotic effects by BIBF 1000 did not occur in n-Ras-mutated t(4;14) positive NCI-H929 (Table 2). In control experiments with L-363 and U-266 cells (Table 2, Figure 6 A) as well as peripheral blood CD19⁺ B lymphocytes (Table 2) and CD19⁺ lymphocytes (data not shown) from healthy donors, no pro-apoptotic effects of BIBF 1000 were detected. FGFR3 overexpression in OPM-2 and KMS-11 is illustrated in Figure 6 B. As shown for OPM-2 and KMS-11 cells in Figure 6 C and 6 D, BIBF 1000 at concentrations effectively inducing apoptosis (0.5 μM) inhibited MAPK phosphorylation in these t(4;14) myeloma cells. MAPK phosphorylation was almost completely abrogated in the absence and partially inhibited in the presence of exogenous IL-6 in case of OPM-2. The latter finding is in line with partial prevention of BIBF 1000-induced apoptosis by IL-6 (Table 2). Indeed, the IL-6-related JAK/STAT-3 signaling cascade was not affected by BIBF 1000 (Figures 6 C).
Consistent with the above findings on apoptosis induction by BIBF 1000, MAPK phosphorylation was not altered in n-Ras mutated NCI-H929 (Figure 6 E) or U-266 cells (Figure 6 F) by the novel indolinone BIBF 1000.

**Apoptotic effects in t(14;16) myeloma cells and inhibition of PI3-kinase/AKT signaling**

In a series of t(14;16) positive MM cell lines tested (MM.1S, MM.1R, ANBL-6, JNJ-3, OCI-My5) and t(16;22) positive RPMI-8226 BIBF 1000 showed variable effects on induction of apoptosis. Antiproliferative and proapoptotic effects of BIBF 1000 in MM.1S and MM.1R were significant and comparable to those with t(4;14). In VEGFR1 expressing MM.1S cells, pro-apoptotic effects of BIBF 1000 were additive to dexamethasone-induced apoptosis, partially antagonized by IL-6, and completely inhibited by the pan-caspase inhibitor z-VAD (see Table 2, Figures 5 and 7 A).

In contrast, BIBF 1000 alone had no marked proapoptotic effects in ANBL-6, JNJ-3, and OCI-My5. However, a consistent additive proapoptotic effect occurred in these latter cell lines by the combination of BIBF 1000 and dexamethasone (Table 2).

In contrast to t(4;14) myeloma cells, induction of apoptosis by BIBF 1000 in MM.1S cells was associated with inhibition of the PI3-kinase/AKT pathway as documented by decreased AKT phosphorylation, while neither MAPK nor STAT3 phosphorylation were affected (Figures 7 B and C). The significance of the PI3-kinase/AKT survival pathway in t(14;16) MM.1S cells is further documented in Figure 7 D showing that similar apoptotic effects were obtained with BIBF 1000 and the PI3-kinase inhibitor Ly294002.

RPMI-8226 cells, carrying a t(16;22), were resistant to pro-apoptotic effects of BIBF 1000 possibly due to an additional k-Ras mutation. As expected, MAPK phosphorylation was not altered by the study drug in this cell line (data not shown).
**Induction of apoptosis by BIBF 1000 in patient myeloma cells.**

Apoptosis was quantified flow cytometrically by annexin V / propidium iodide staining in freshly isolated and subsequently CD138⁺ sorted cells derived from twelve patients with active MM with or without t(4;14) (Table 2). In line with the data from t(4;14) positive cell lines, we found consistent induction of apoptosis by BIBF 1000 (500 nM) in CD138⁺ sorted marrow cells from the three patients with t(4;14) positive myeloma (Table 2). Again, BIBF 1000-induced apoptosis was partially antagonized by exogeneous IL-6 (Table 2). In addition, we observed additive effects of BIBF 1000 and dexamethasone in two of those patients (Table 2, Figure 8).

Apart from these findings in myeloma cells with defined cytogenetic abnormalities, BIBF 1000 induced apoptosis to a variable extent in CD138⁺ marrow cells from 4 out of 10 patients with active MM carrying neither the t(4;14) nor the t(14;16) translocations (Table 2).
Discussion

BIBF 1000 is a novel indolinone-derived RTKI primarily targeting VEGFRs 1 through 3, FGFR1 and 3, and PDGFR α kinases. From our results it can be inferred that BIBF 1000 also interferes with a paracrine signaling pathway triggered by TGF-β, another key cytokine in myeloma-marrow stroma interactions. The data presented herein delineate two types of in vitro effects of BIBF 1000 in myeloma that both have implications for understanding the tumor biology and for clinical applications of RTKIs in this heterogeneous disease.

First and irrespective of the type of myeloma cells studied, BIBF 1000 strongly inhibited stroma-derived IL-6 release in the myeloma microenvironment. This effect of BIBF 1000 can in part be attributed to inhibition of paracrine signals through VEGF, bFGF and TGF-β. In addition, it may also be a consequence of the variably decreased adherence of myeloma to stroma cells (compare Figure 4). However, for the first time, the data obtained with BIBF 1000 demonstrate that inhibition of paracrine mechanisms significantly reduces microenvironmental IL-6 production both in the absence (U-266, KMS-11) or presence (RPMI-8226) of conserved myeloma cell adherence to marrow stroma cells. These findings extend previous reports on decreased IL-6 production in myeloma-stroma cell co-cultures exposed to investigational RTKIs targeting VEGFRs, such as PTK787/ZK222584 or GW654652. Furthermore, given the importance of IL-6 as a tumor growth and resistance factor in MM, it can be speculated that BIBF 1000 may have indirect pro-apoptotic effects in MM in vivo through inhibition of paracrine IL-6 circuits and should also be suited to revert IL-6-mediated conventional drug resistance.

The second type of BIBF 1000-mediated effects comprises inhibition of proliferation and direct induction of myeloma cell apoptosis. In this respect, the sensitivity of myeloma cells towards BIBF 1000 varied considerably and was related
to subgroups of myeloma cells with defined cytogenetic abnormalities. The anti-proliferative activity of BIBF 1000 appeared to be most marked in, though not restricted to myeloma cell lines carrying the translocations t(4;14) or t(14;16).

A similar subgroup preference was evident for the pro-apoptotic effects of BIBF 1000. Strong anti-proliferative and pro-apoptotic activities of BIBF 1000 and almost complete inhibition of stroma adherence were observed in cell lines with t(4;14) and different activating mutations of FGFR3 (OPM-2, KMS-11, and KMS-18) as well as wildtype FGFR3 (UTMC-2) and in freshly isolated CD138+ myeloma cells from the marrow of patients with t(4;14) positive MM (Table 2). The proapoptotic effects were paralleled by interruption of receptor signaling through MAPK (Figure 6 C and D). These findings and the marked selectivity of the drug effects strongly support the notion that FGFR3 overexpression and mutation is a dominant transforming event in this type of myeloma cells. In this respect, our results with BIBF 1000 in FGFR3 mutated myeloma cell lines are in line with recently reported effects of PD173074 and CHIR-258, experimental RTKIs also targeting FGFRs.48, 55

Notably, proapoptotic effects by BIBF 1000 did not occur in n-Ras-mutated t(4;14) positive NCI-H929 cells (Figure 6 E), implicating that the presence of mutated Ras in MM cells constitutively activates MAPK signaling independent from upstream receptor tyrosine kinase (RTK) activity.

Furthermore, induction of apoptosis by BIBF 1000 was only partially antagonized by adding exogenous IL-6 at saturating concentrations. Thus, abnormal signaling through the FGFR3 pathway appears to be crucial for tumor cell survival in these cell lines while the IL-6 signal is dispensable and can only partly sustain cell survival in the absence of deregulated FGFR3 signaling. The observations demonstrate a hierarchy of survival pathways in this myeloma subgroup that may have implications for therapeutic targeting.
In MM.1S and MM.1R cells, characterized by translocation t(14;16) (IgH/c-maf), VEGFR1 expression and sensitivity to autocrine stimulation by VEGF, similar antiproliferative and proapoptotic effects by BIBF 1000 were observed. Of note, despite the finding that BIBF 1000 alone had no marked effect in a series of other t(14;16) positive cell lines, a consistent additive proapoptotic effect occurred in these cells (ANBL-6, JJN-3, OCI-My5) upon exposure to BIBF 1000 and dexamethasone. In t(14;16) MM.1S cells, induction of apoptosis by BIBF 1000 appeared to be related to the inhibition of the PI3-kinase/AKT pathway indicating its association with inhibition of VEGFR signaling. Recently, MM.1S have been shown to be protected from apoptosis through VEGF-induced upregulation of Mcl-1, an anti-apoptotic member of the Bcl-2 family. Therefore, the observed effects of BIBF 1000-mediated interruption of VEGFR signaling in this cell line were not unexpected. As with t(4;14) cell lines, induction of apoptosis by BIBF 1000 in MM.1S cells was only partly prevented by exogenous IL-6, although IL-6 receptor signaling through the JAK/STAT cascade was not impaired. This finding again points to a hierarchy of survival pathways that may characterize this type of myeloma cells. In line with the findings in t(4;14) positive MM, k-Ras mutated t(16;22) postive RPMI-8226 cells were resistant to BIBF 1000 treatment even in the presence of dexamethasone.

Notably, normal CD19+ B lymphocytes, CD19- lymphocytes as well as L363 and U-266 cells were insensitive to BIBF 1000 treatment with respect to apoptosis induction over the range of concentrations tested indicating that merely toxic effects of the study drug can be excluded.

Taken together, our data provide the rationale for currently ongoing phase I clinical evaluation of this novel class of indolinone derivatives. They also suggest that future clinical trials on RTKIs with similar target profiles should be designed to detect reversal of resistance to classical anti-myeloma agents, e. g. dexamethasone, that
may be achieved through the inhibition of IL-6 production in the myeloma-marrow microenvironment. Potential clinical applications should particularly focus on, but not be limited to cytogenetically defined myeloma subgroups, such as those with t(4;14) or t(14;16) in which myeloma survival and stroma interactions appear to be driven, at least in part, by VEGFR or mutant FGFR signaling. Finally, the Ras mutational status may also have implications for treatment with this class of targeted drugs.
Acknowledgments

D.W. contributed experiments to fulfill requirements for her MD thesis.

We thank Takemi Otsuki from Kawasaki Medical School, Okayama, Japan, for kindly providing the KMS-11 and KMS-18 myeloma cell lines and Nancy L. Krett, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois, USA for supplying MM.1S and MM.1R cell lines. We thank Leif Bergsagel, Mayo Clinic, Scottsdale, Arizona, USA for supplying the OCI-My5 and UTMC-2 lines and Manik Chatterjee, Max-Delbrueck Zentrum, Berlin-Buch, Berlin, Germany for kindly providing the ANBL-6 myeloma cell line. We thank Christina Burhoi for excellent technical assistance.
Figure legends

Figure 1.

Inhibition of VEGFR2 (KDR) and FGFR3 phosphorylation by BIBF 1000. (A) Cultured marrow stroma cells were exposed to VEGF (50 ng/mL) in the presence of increasing concentrations of BIBF 1000 for 5 minutes. Dose-dependent abrogation of VEGFR2 phosphorylation (upper panels: anti-p-Tyr100 immunoblots, densitometry) and corresponding immunoblots of total VEGFR2 (lower panel) are shown. (B) OPM-2 cells known to express a constitutively active FGFR3 mutant were incubated with increasing concentrations of BIBF 1000 for 5 minutes. FGFR3 phosphorylation was inhibited in a dose-dependent manner (upper panels: anti-p-Tyr85 immunoblots, densitometry). Lower panel shows corresponding immunoblots of total FGFR3.

Figure 2.

Effects of BIBF 1000 on stroma-derived interleukin-6 (IL-6) release and related inhibition of mitogen activated protein kinases (MAPK) phosphorylation. (A and B) Effects of BIBF 1000 on bone marrow stroma cell (BMSC)-derived interleukin-6 (IL-6) release: BIBF 1000 (0.5 µM) significantly inhibited basal IL-6 release from BMSCs and IL-6 secretion induced by VEGF_{121}, VEGF_{165}, bFGF, and TGF-β (105.3 ± 28.1 vs. 37.3 ± 16.1 [vehicle control vs. BIBF 1000]; 169.2 ± 23.4 vs. 45.3 ± 16.6 [VEGF_{121} vs. VEGF_{121} + BIBF 1000]; 172.0 ± 22.3 vs. 60.1 ± 21.9 [VEGF_{165} vs. VEGF_{165} + BIBF 1000]; 185.1 ± 17.3 vs. 44.7 ± 14.3 [bFGF vs. bFGF+ BIBF 1000]; 499.5 ± 33.8 vs. 195.7 ± 36.7 [TGF-β vs. TGF-β+ BIBF 1000]), respectively; p<.001). In contrast, IL-6 release upon exposure to TNF-α or IL-1β was not significantly reduced (754.7 ± 122.6 vs. 547.4 ± 83.0 [TNF-α vs. TNF-α+ BIBF 1000]; 1881.7 ± 122.3 vs. 1855.8 ± 122.9 [IL-1β vs. IL-1β + BIBF 1000]). IL-6
concentrations were determined in triplicates from supernatants of BMSC cultures derived from different myeloma patients \((n = 4)\). BMSCs were starved prior to incubation with either \(\text{VEGF}_{121}, \text{VEGF}_{165}, \text{bFGF}, \text{TGF-}\beta, \text{TNF-}\alpha, \text{or IL-1}\beta \pm \text{BIBF 1000}\) and kept in serum-free conditions for 72 hours. Data are presented as means ± SE. The Wilcoxon test was employed to identify differences between controls and corresponding BIBF 1000-treated BMSCs. (C) Inhibition of MAPK phosphorylation by BIBF 1000 in BMSCs: Subconfluent BMSCs were starved for 4 hours in serum-free medium and subsequently exposed for 2 hours to either \(\text{VEGF (50 ng/mL)}, \text{bFGF (10 ng/mL)}, \text{TGF-}\beta (10 \text{ ng/mL}), \text{TNF-}\alpha (10 \text{ ng/mL})\) or \(\text{IL-1}\beta (10 \text{ ng/mL})\) in the absence or presence of BIBF 1000 \((1, 5, \text{or } 10 \text{ \mu M})\), to BIBF alone \((10 \text{ \mu M})\) or to the MAPK-inhibitor PD98059 \((20 \text{ \mu M})\). Proteins were extracted, boiled, and separated by SDS-electrophoresis. Subsequent immunoblotting was performed using a rabbit polyclonal p-MAPK (p44/42) antibody and a corresponding goat anti-rabbit-HRP conjugated secondary antibody. Notably, inhibition of MAPK phosphorylation by BIBF 1000 was most effective in BMSCs exposed to VEGF, bFGF, or TGF-\beta. The results shown are representative of 3 independent experiments.

**Figure 3.**

*Interleukin-6 (IL-6) secretion in transwell and contact co-cultures of bone marrow stroma (BMSCs) and myeloma (MM) cells is significantly inhibited by BIBF 1000.* (A) Control experiments in BMSC monocultures showed dose-dependent inhibition of IL-6 release by BIBF 1000 \((0.5 \text{ \mu M})\). (B) Basal IL-6 secretion by myeloma cell lines ranged near or below the detection limit of the assay. (C-H) As compared to BMSC monocultures, IL-6 secretion was increased in both transwell (C-E) and contact (F-H) co-cultures of BMSCs with either U-266, RPMI-8226, or KMS-11 cells. Exposure to BIBF 1000 \((0.125 – 1.0 \text{ \mu M})\) resulted in almost complete abrogation of
IL-6 secretion in both types of co-cultures. (I-K) In transwell co-cultures of BMSCs and patient-derived CD138\(^+\)-sorted MM cells, a similar increase in IL-6 secretion as compared to the respective monocultures and its dose-dependent inhibition by BIBF 1000 was observed. IL-6 concentrations were determined in serum-free supernatants of 72 hour-cultures. Samples were measured in triplicates and the results are presented as means ± SE of at least 3 independent experiments. Significance of group differences was analyzed by the Mann-Whitney rank sum test. * P <.05, ** P <.005, *** P <.0001 versus controls without BIBF 1000.

Figure 4.
Inhibition of myeloma cell adhesion to bone marrow stroma cells (BMSCs) by BIBF 1000. Contact co-cultures were performed with confluent monolayers of 1 x 10\(^5\) BMSCs and 2 x 10\(^6\) CFSE-prelabeled RPMI-8226, U-266, OPM-2, or KMS-11 cells, respectively. Cell cultures were incubated in the absence or in the presence of BIBF 1000 (0.25 to 5.0 µM) for 24 hours. Subsequently, non-adherent cells were washed off three times. The remaining adherent cells were trypsinized and quantified by flow cytometry. Data are presented as mean ratios of adherent MM cells over BMSCs from 3 independent experiments for each cell line. Analysis of significance for overall group differences was performed by the Kruskal-Wallis test (U-266, OPM-2, and KMS-11: P =.0001; RPMI-8226: n.s.).

Figure 5.
Dose-dependent inhibition of myeloma cell proliferation by BIBF 1000. (A, B, C) 5 x 10\(^4\) myeloma cells per well were seeded onto 96 well plates and cultured in RPMI-1640 medium with or without BIBF 1000. Cells were pulsed with 0.625 µCi \(^3\)H-thymidine per well for 72 hours. Cells were harvested and \(^3\)H-thymidine incorporation
was counted. $^{3}$H-thymidine uptake is shown as mean values of triplicate determinations from 2 independent series of experiments for each cell line. $^{3}$H-thymidine uptake was normalized to the controls without BIBF 1000. A ≥ 70 % inhibition of proliferation by 1.0 µM BIBF 1000 was observed in the t(4;14) positive KMS-11, OPM-2, and NCI-H929 cells and in the t(14;16) positive MM.1S and MM.1R cells ($P < .001$, BIBF 1000 [1.0 µM] vs. control w/o BIBF 1000). BIBF 1000 (1 µM) inhibited the proliferation of U-266 and L-363 by approximately 50 %, while it did not or only marginally influence the proliferation of the t(14;16) positive cell lines JJN-3 and ANBL-6 as well as of the t(16;22) positive cell line RPMI-8226.

**Figure 6.**

**BIBF 1000-induced apoptosis in t(4;14) positive myeloma cells and related inhibition of MAPK (p44/42) phosphorylation.** (A) Dose-dependent induction of apoptosis in t(4;14) positive, fibroblast growth factor receptor 3 (FGFR3)-overexpressing OPM-2 cells by BIBF 1000 (125 – 500 nM, upper panel). Induction of apoptosis was completely reverted by the pan-caspase-inhibitor z-VAD-FMK (100 µM). No significant BIBF 1000-induced apoptosis occurred in U-266 cells serving as a t(4;14) negative control (lower panel). (B) FGFR3 protein expression in t(4;14) positive OPM-2 and KMS-11 versus t(4;14) negative RPMI-8226 and U-266 cells. Representative immunoblots are shown. (C) Inhibition of MAPK phosphorylation in t(4;14) OPM-2 cells. Constitutive and IL-6-induced MAPK phosphorylation were almost completely or partially inhibited by BIBF 1000 while STAT3 phosphorylation was not affected. (D) Inhibition of MAPK phosphorylation in t(4;14) KMS-11 cells. Results were similar to those obtained with OPM-2 cells. (E, F) Neither MAPK nor STAT3 phosphorylation were altered by BIBF 1000 in N-Ras mutated t(4;14) positive NCI-H929 cells (E) and in t(4;14) negative U-266 cells (F). In C through F, myeloma
cell lines were starved for 2 hours and exposed to IL-6 (10 ng/mL) and/or BIBF 1000 (500 nM) for 5 minutes prior to extraction of proteins by RIPA-buffer containing protease and phosphatase inhibitors.

Figure 7.
BIBF 1000-induced apoptosis in t(14;16) positive MM.1S cells and related inhibition of the phosphatidylinositol-3 kinase (PI3-K)/AKT pathway. (A) BIBF 1000 induced apoptosis in native t(14;16) positive MM.1S cells and had additive apoptotic effects in the presence of dexamethasone (Dex) (compare percentages of annexin V-positive, PI-negative cells, lower right quadrants). Apoptosis induced by BIBF 1000 was partially antagonized by interleukin-6 (IL-6) at saturating concentrations (10 ng/mL) and completely prevented by the pan-caspase inhibitor z-VAD. (B) BIBF 1000 had no effect on MAPK or STAT3 phosphorylation in MM.1S cells. (C) The PI3-K/AKT pathway was inhibited by BIBF 1000 both in the absence and presence of IL-6 as shown by decreased phosphorylation of AKT. (D) BIBF 1000 (0.5 µM) and the PI3-K inhibitor Ly294002 (10 µM) had similar effects on the induction of early and late apoptosis in MM.1S cells (annexin V-positive (+ve), PI-negative (-ve) and annexin V-positive, PI-positive cells, respectively).

Figure 8:
Induction of apoptosis by BIBF 1000 in patient myeloma cells. Quantification of apoptosis by flow cytometry in CD138+ sorted cells from the marrow of a patient with t(4;14) positive myeloma, [pt. #3]). Increased early/late apoptosis by BIBF 1000, dexamethasone, and their combination is depicted in row 1. Row 2 shows partial reversal of apoptosis by IL-6.
References


47. Mitsiades CS, Mitsiades N, Kung AL, et al. The IGF-IGF-R system is a major therapeutic target for multiple myeloma, other hematologic malignancies and solid tumors. Blood. 2002;100:170a


53. Podar K, Catley LP, Tai YZ, et el. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood. 2004;103:3474-3479.


Figures

A  
Bone marrow stroma cells (BMSC)

anti-p-Tyr100 →

OD

anti-p-Tyr100 densitometry

anti-KDR →

VEGF (50 ng/mL)

- + + + + + + + + + + +
20 μM 10 μM 5 μM 2.5 μM 1.25 μM 625 nM 312 nM 156 nM 78 nM 39 nM

BIBF 1000

B  
OPM-2 myeloma cells

anti-p-Tyr85 →

OD

anti-p-Tyr85 densitometry

anti-FGFR3 →

w/o 20 μM 10 μM 5 μM 2.5 μM 1.25 μM 625 nM 312 nM 156 nM 78 nM 39 nM

BIBF 1000

Figure 1
Figure 2
Figure 3
Figure 4

The graph shows the ratio of adherent MM cells to BMSCs as a function of BIBF 1000 concentration. Different cell lines (RPMI-8226, OPM-2, KMS-11, U-266) are represented by various markers, demonstrating varying sensitivities to the drug concentration.
Figure 5
Figure 6
Figure 7
Figure 8
**Tables**

**Table1: Receptor tyrosine kinases inhibited by BIBF 1000**

<table>
<thead>
<tr>
<th>Receptor tyrosine kinase</th>
<th>IC$_{50}^{BIBF 1000}$ [nM]</th>
</tr>
</thead>
<tbody>
<tr>
<td>VEGFR1</td>
<td>40</td>
</tr>
<tr>
<td>VEGFR2</td>
<td>28</td>
</tr>
<tr>
<td>VEGFR3</td>
<td>142</td>
</tr>
<tr>
<td>FGFR1</td>
<td>43</td>
</tr>
<tr>
<td>FGFR3</td>
<td>52</td>
</tr>
<tr>
<td>PDGFRa</td>
<td>35</td>
</tr>
<tr>
<td>EGFR</td>
<td>&gt;50.000</td>
</tr>
<tr>
<td>HER-2</td>
<td>&gt;10.000</td>
</tr>
<tr>
<td>IGFR1</td>
<td>&gt;10.000</td>
</tr>
<tr>
<td>InsR</td>
<td>&gt;10.000</td>
</tr>
<tr>
<td>HGFR</td>
<td>&gt;10.000</td>
</tr>
<tr>
<td>CDK1</td>
<td>&gt;10.000</td>
</tr>
<tr>
<td>CDK2</td>
<td>&gt;10.000</td>
</tr>
<tr>
<td>CDK4</td>
<td>&gt;10.000</td>
</tr>
</tbody>
</table>
Table 2: Induction of apoptosis by BIBF 1000 in MM cells

<table>
<thead>
<tr>
<th>MM cell</th>
<th>karyotypic abnormalities</th>
<th>FGFR3 mutation</th>
<th>ras mutation</th>
<th>Apoptotic cells (% means +/- SE)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>w/o BIBF 1000</td>
<td>BIBF 1000 500 nM</td>
<td>% increase over vehicle control</td>
<td>BIBF 1000 + IL-6 500 nM</td>
</tr>
<tr>
<td>KMS-11</td>
<td>t(4;14) t(14;16)</td>
<td>+ (Y373C)</td>
<td>-</td>
<td>17.8 ± 3.4</td>
</tr>
<tr>
<td>KMS-18</td>
<td>t(4;14)</td>
<td>-</td>
<td>+ (G384D)</td>
<td>10.2 ± 2.5</td>
</tr>
<tr>
<td>OPM-2</td>
<td>t(4;14)</td>
<td>-</td>
<td>+ (K650E)</td>
<td>13.2 ± 3.5</td>
</tr>
<tr>
<td>UTMG-2</td>
<td>t(4;14)</td>
<td>-</td>
<td>+ (wt)</td>
<td>32.2 ± 3.6</td>
</tr>
<tr>
<td>NCI/H929</td>
<td>t(4;14)</td>
<td>-</td>
<td>+ (wt) + W13</td>
<td>26.2 ± 2.3</td>
</tr>
</tbody>
</table>

| pt. 98 | t(4;14) | - | + | 21.6 | 32.5 | 10.9 | 9.8 | 54.5 | 44.7 | ND | ND | ND | ND |
| pt. 97 | t(4;14) | - | + | 28.5 | 49.3 | 10.8 | 30.5 | 49.3 | 10.8 | 28.2 | 53.8 | 64.2 | 10.6 |

| MM.15   | t(4;14) | - | - | 20.4 ± 1.7 | 47.9 ± 3.0 | 26.6 ± 3.2 | 0.001 | 31.9 ± 4.2 | 0.027 | 53.8 ± 3.9 | 0.001 | 82.2 ± 2.7 | 25.2 ± 4.2 | 0.001 |
| MM.1R   | t(4;14) | - | - | 25.5 ± 2.9 | 40.8 ± 5.3 | 15.3 ± 5.3 | 0.019 | 30.9 ± 9.1 | n.s. | 25.6 ± 24 | n.s. | 37.8 ± 3.8 | 12.2 ± 2.5 | 0.06 |
| ANBL-6  | t(4;14) | - | - | 8.1 ± 5 | 10.2 ± 1.2 | 2.1 ± 1.1 | n.s. | ND | ND | 29.2 ± 0.7 | 0.021 | 46.9 ± 0.9 | 17.7 ± 1.1 | 0.021 |
| JUN-3   | t(4;14) | - | - | 24.6 ± 3.8 | 17.2 ± 2.8 | -4.4 ± 1.6 | n.s. | ND | ND | 36.9 ± 5.8 | n.s. | 44.6 ± 8.4 | 7.7 ± 3.4 | n.s. |
| OCI-MY5 | t(4;14) | - | - | 31.2 ± 3.8 | 32.0 ± 2.7 | 0.8 ± 1.6 | n.s. | ND | ND | 48.9 ± 10.3 | n.s. | 55.6 ± 10.0 | 6.7 ± 0.6 | n.s. |
| RPMI-8226 | t(4;14) | - | + W/12 | 8.6 ± 2.7 | 8.7 ± 3.3 | 1.1 ± 3.3 | n.s. | 10.9 ± 2.4 | n.s. | 9.5 ± 1.4 | n.s. | 12.3 ± 1.7 | 2.8 ± 1.7 | n.s. |

| U-266   | - | - | - | 8.7 ± 1.2 | 10.8 ± 1.4 | 2.1 ± 0.6 | n.s. | 10.1 ± 1.5 | n.s. | 9.4 ± 1.5 | n.s. | 12.0 ± 1.8 | 2.6 ± 0.7 | n.s. |
| L363    | - | - | - | 17.8 | 33.6 | 15.8 | 17.8 | 33.6 | 15.8 | ND | ND | ND | ND |
| pt. 94  | - | - | - | 6.6 | 37.5 | 30.9 | 14.9 | ND | ND | 43.8 | n.s. | 59.5 | 24.7 |
| pt. 89  | - | - | - | 17.3 | 31.6 | 14.3 | ND | ND | ND | ND | ND | ND | ND |
| pt. 87  | - | - | - | 31.9 | 39.1 | 7.2 | ND | ND | 60.7 | n.s. | 71.9 | 11.2 |
| pt. 88  | - | - | - | 23.0 | 15.8 | -7.2 | ND | ND | 29.4 | 27.7 | -1.7 |
| pt. 89  | - | - | - | ND | 8.8 | 8.9 | .1 | ND | ND | 7.6 | ND | ND | ND |
| pt. 90  | - | - | - | 25.3 | 28.5 | 3.2 | ND | ND | ND | ND | ND | ND | ND |
| pt. 91  | - | - | - | ND | 8.9 | 9.9 | 1.0 | ND | ND | 9.4 | 8.3 | -1.1 |
| pt. 92  | - | - | - | ND | 6.8 | 9.2 | 2.4 | ND | ND | 41.1 | 40.7 | 7.6 |
| pt. 93  | - | - | - | ND | 6.7 | 7.4 | .7 | 5.9 | 14.2 | 10.2 | -4.0 |

<table>
<thead>
<tr>
<th>w/o BIBF1000</th>
<th>BIBF1000</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 nM</td>
<td>500 nM</td>
</tr>
<tr>
<td>PBBLs</td>
<td>4.6 ± 1.0</td>
</tr>
</tbody>
</table>

Data represent means +/- SE of 3 independent experiments for each type of myeloma cell line.

P1: 500 nM BIBF 1000 versus vehicle control.
P2: 500 nM BIBF 1000 + IL-6 versus 500 nM BIBF 1000.
P3: 10 μM Dex versus vehicle control.
P4: 500 nM BIBF1000 + 10 μM Dex versus Dex alone (10 μM).
pM: CD138+ sorted cells from MM patients.
PBBLs, peripheral blood B lymphocytes, obtained from 5 healthy volunteers.
Dex, dexamethasone; IL-6, interleukin-6; FGFR3, fibroblast growth factor receptor 3.
Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups

Guido Bisping, Martin Kropff, Doris Wenning, Britta Dreyer, Sergey Bessonov, Frank Hilberg, Gerald J Roth, Gerd Munzert, Martin Stefanic, Matthias Stelljes, Christian Scheffold, Carsten Muller-Tidow, Peter Liebisch, Nicola Lang, Joelle Tchinda, Hubert L Serve, Rolf M Mesters, Wolfgang E Berdel and Joachim Kienast